Clinical trial · no report yet · Phase 2
NCT06567743
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
- NCT06567743 ↗
- Recruiting
- CG Oncology, Inc.
- 10 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 4 | |
| X threads | 4 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- High-Risk Non-Muscle-Invasive Bladder Cancer
- Interventions
- Cretostimogene Grenadenorepvec
- Arms
- Experimental: Cohort A, Arm 1 · Experimental
- Experimental: Cohort A, Arm 2 · Experimental
- Experimental: Cohort A, Arm 3 · Experimental
- Experimental: Cohort B, Arm 1 · Experimental
- Experimental: Cohort B, Arm 2 · Experimental
- Experimental: Cohort CX, Arm 1 · Experimental
- Experimental: Cohort CX, Arm 2 · Experimental
- Enrollment
- 325 (estimated)
- Primary outcomes
- Cohort A (Arm 1 and 2): Complete response rate
- Cohort A (Arm 3): High- Grade Event-Free Survival
- Cohort B (Arm 1): Complete response rate
- Cohort B (Arm 2): High-Grade Event-Free Survival
- Cohort CX (Arms 1 and 2): High-Grade Event-Free Survival
- Cohort CX (Arms 1 and 2): Safety
- Sponsor
- CG Oncology, Inc.
- Start
- Sep 16, 2024
- Primary completion
- Mar 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06567743 · updated Sep 3, 2026